Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AGIO

Agios Pharmaceuticals Inc

Nov 30 • 04:00PM ET

22.23

Dollar change +0.03
Percentage change 0.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.95	Insider Own	1.96%	Shs Outstand	55.04M	Perf Week	1.23%
Market Cap	1.24B	Forward P/E	-	EPS next Y	-6.34	Insider Trans	-6.54%	Shs Float	54.80M	Perf Month	5.81%
Income	-219.62M	PEG	-	EPS next Q	-1.62	Inst Own	100.36%	Short Float / Ratio	10.99% / 11.22	Perf Quarter	-18.96%
Sales	24.03M	P/S	51.70	EPS this Y	-47.28%	Inst Trans	-3.13%	Short Interest	6.02M	Perf Half Y	-13.54%
Book/sh	15.87	P/B	1.40	EPS next Y	-1.70%	ROA	-20.08%	Target Price	38.00	Perf Year	-22.81%
Cash/sh	11.59	P/C	1.92	EPS next 5Y	39.00%	ROE	-22.68%	52W Range	19.80 - 31.87	Perf YTD	-20.83%
Dividend	-	P/FCF	-	EPS past 5Y	8.92%	ROI	-23.17%	52W High	-30.25%	Beta	0.93
Dividend %	-	Quick Ratio	11.76	Sales past 5Y	8.87%	Gross Margin	26.89%	52W Low	12.30%	ATR	0.96
Employees	389	Current Ratio	12.06	Sales Q/Q	110.44%	Oper. Margin	-1599.59%	RSI (14)	50.93	Volatility	4.00% 4.59%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	-9.80%	Profit Margin	-913.95%	Rel Volume	0.91	Prev Close	22.20
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Nov 02 BMO	Payout	-	Avg Volume	536.88K	Price	22.23
Recom	1.75	SMA20	1.09%	SMA50	-1.56%	SMA200	-9.96%	Volume	487,158	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$80
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy	$117
Apr-11-18	Reiterated	Credit Suisse	Outperform	$80 → $95
Feb-15-18	Reiterated	SunTrust	Buy	$80 → $101

Show Previous Ratings

Nov-21-23 10:56AM	Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment (Zacks)
Nov-20-23 07:00AM	Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Nov-03-23 12:10PM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.10%
11:06AM	Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales (Zacks)
Nov-02-23 09:32AM	Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net Revenue (GuruFocus.com)
09:05AM	Loading…
09:05AM	Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition (GlobeNewswire)
07:10AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 07:00AM	Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023 (GlobeNewswire)
Sep-07-23 11:30AM	Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report? (Zacks)
Aug-29-23 07:00AM	Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023 (GlobeNewswire)
Aug-10-23 06:08AM	The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake (American City Business Journals)
Aug-04-23 05:32PM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:10AM	Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line (Zacks)
06:04AM	Agios Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
11:53PM	Loading…
Aug-03-23 11:53PM	Q2 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:55AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:54AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
06:35AM	Agios Reports Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire)
06:30AM	Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera (GlobeNewswire)
Jul-18-23 09:55AM	Should You Buy Agios Pharmaceuticals (AGIO) After Golden Cross? (Zacks)
Jul-17-23 09:55AM	Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet (Zacks)
Jul-13-23 07:00AM	Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023 (GlobeNewswire)
Jun-28-23 09:40AM	Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year? (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 02:23PM	Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat (Benzinga)
06:30AM	Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response (GlobeNewswire)
Jun-12-23 09:55AM	Wall Street Analysts Believe Agios Pharmaceuticals (AGIO) Could Rally 39.16%: Here's is How to Trade (Zacks)
Jun-05-23 07:00AM	Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023 (GlobeNewswire)
May-30-23 09:45AM	Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
09:55AM	Loading…
May-25-23 09:55AM	Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect? (Zacks)
07:00AM	Agios Appoints Catherine Owen to Board of Directors (GlobeNewswire)
May-11-23 10:00AM	Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress (GlobeNewswire)
May-09-23 09:55AM	Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know (Zacks)
May-08-23 07:55AM	An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% Undervalued (Simply Wall St.)
May-05-23 10:50AM	Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
May-04-23 11:23PM	Q1 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +7.65%
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Agios Reports Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
Apr-19-23 07:00AM	Agios Appoints Jeffrey Capello to Board of Directors (GlobeNewswire)
Apr-13-23 07:00AM	Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire) +5.29%
Apr-12-23 08:00AM	Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero (PR Newswire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Apr-03-23 07:00AM	Agios Publishes 2023 Environmental, Social and Governance (ESG) Report (GlobeNewswire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 09:10AM	We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely (Simply Wall St.)
Mar-05-23 05:20AM	TipRanks Perfect 10 List: These 2 Healthcare Stocks Look Compelling at Current Levels (TipRanks)
Mar-02-23 08:26AM	Agios to Participate in March Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Agios Launches Red Cell Revolution in Recognition of Rare Disease Day (GlobeNewswire)
Feb-24-23 12:00PM	Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
11:49AM	Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss (Zacks)
Feb-23-23 08:45AM	Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates (Zacks)
08:38AM	Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:00AM	Agios Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-09-23 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-23 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023 (GlobeNewswire)
Jan-15-23 08:56AM	Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago (Simply Wall St.)
Jan-08-23 08:00PM	Agios Unveils 2023-2026 Value-driving Catalysts Enabling Companys Vision to Transform Patient Outcomes in Rare Diseases (GlobeNewswire)
Jan-03-23 05:57PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (GlobeNewswire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-21-22 08:00AM	Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 (GlobeNewswire)
Dec-11-22 07:00PM	Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-10-22 06:30PM	Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent - and -Thalassemia at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-06-22 07:00AM	Agios Appoints Tsveta Milanova as Chief Commercial Officer (GlobeNewswire)
Nov-30-22 08:00AM	Agios to Participate in December Investor Conference (GlobeNewswire)
Nov-17-22 05:52AM	The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup (American City Business Journals) +5.38%
Nov-11-22 11:03AM	Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients (Benzinga)
Nov-10-22 04:01PM	PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients (GlobeNewswire) +9.15%
Nov-09-22 05:36AM	Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%? (Simply Wall St.)
Nov-04-22 12:20PM	Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-03-22 09:00AM	Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition (GlobeNewswire) -5.25%
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Edited Transcript of AGIO.OQ earnings conference call or presentation 3-Nov-22 12:00pm GMT (Thomson Reuters StreetEvents)
07:00AM	Agios Reports Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-27-22 04:01PM	Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty (GlobeNewswire)
Oct-20-22 07:00AM	Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-02-22 09:44AM	We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-26-22 07:13PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
Sep-19-22 07:00AM	Agios Appoints Cecilia Jones as Chief Financial Officer (GlobeNewswire) +5.16%
Sep-16-22 06:41AM	Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients (GlobeNewswire) -9.51%
Sep-06-22 08:05AM	A Technical Strategy to 'Buy' Agios Pharmaceuticals (TheStreet.com)
Sep-02-22 04:02PM	Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating (Investor's Business Daily)
Aug-24-22 07:00AM	Agios to Participate in September Investor Conferences (GlobeNewswire) +6.42%
Aug-18-22 06:35PM	Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency (GlobeNewswire)
Aug-15-22 08:00AM	Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors (GlobeNewswire)
Aug-11-22 06:35PM	Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent - and -Thalassemia (GlobeNewswire) -7.90%
10:01AM	ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox (GlobeNewswire)
Aug-08-22 06:36PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer (GlobeNewswire)
08:41AM	Even after rising 38% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 49% over the past five years (Simply Wall St.)
Aug-05-22 12:20PM	Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
Aug-04-22 08:45AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.67%
07:00AM	Agios Reports Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 07:00AM	Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-12-22 04:01PM	Former Alexion executive to take helm at Agios Pharmaceuticals (American City Business Journals)
04:01PM	Agios Appoints Brian Goff as Chief Executive Officer (GlobeNewswire)
Jun-13-22 06:30AM	CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease (GlobeNewswire) -6.11%
Jun-10-22 10:30AM	Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress (GlobeNewswire) -5.61%
Jun-02-22 05:39PM	Top Small-Cap Stocks for June 2022 (Investopedia)
May-17-22 12:13PM	Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff (Benzinga)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Cecilia	Chief Financial Officer	Sep 28	Sale	24.79	2,179	54,017	9,575	Sep 28 04:02 PM
Jones Cecilia	Chief Financial Officer	Sep 26	Option Exercise	0.00	7,472	0	11,754	Sep 28 04:02 PM
Burns James William	Chief Legal Officer	Aug 17	Sale	26.28	6,395	168,061	23,890	Aug 21 04:03 PM
Ballal Rahul D.	Director	Aug 11	Option Exercise	0.00	2,302	0	2,302	Aug 15 04:06 PM
Smith Cynthia	Director	Aug 11	Option Exercise	0.00	2,302	0	2,302	Aug 15 04:04 PM
Foster-Cheek Kaye I	Director	Aug 09	Option Exercise	18.09	25,000	452,250	36,524	Aug 11 04:04 PM
Foster-Cheek Kaye I	Director	Aug 09	Sale	25.96	25,000	648,888	11,524	Aug 11 04:04 PM
Goff Brian	Chief Executive Officer	Aug 08	Option Exercise	0.00	22,691	0	36,770	Aug 10 04:07 PM
Goff Brian	Chief Executive Officer	Aug 08	Sale	25.48	10,178	259,335	26,592	Aug 10 04:07 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 07	Sale	25.39	2,918	74,096	2,741	Aug 09 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 01	Option Exercise	0.00	4,150	0	6,891	Aug 02 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Aug 01	Sale	26.26	1,232	32,352	5,659	Aug 02 04:02 PM
Goff Brian	Chief Executive Officer	Jun 30	Sale	28.36	11,449	324,694	14,079	Jun 30 04:05 PM
FOUSE JACQUALYN A	Director	Jun 30	Sale	28.36	10,718	303,962	106,966	Jun 30 04:07 PM
Gheuens Sarah	Chief Medical Officer	Jun 30	Sale	28.36	1,707	48,411	24,159	Jun 30 04:06 PM
Burns James William	Chief Legal Officer	Jun 30	Sale	28.36	1,707	48,411	30,285	Jun 30 04:09 PM
Milanova Tsveta	Chief Commercial Officer	Jun 30	Sale	28.36	1,618	45,886	3,831	Jun 30 04:02 PM
Jones Cecilia	Chief Financial Officer	Jun 30	Sale	28.36	1,597	45,291	3,783	Jun 30 04:03 PM
FOUSE JACQUALYN A	Director	Jun 28	Option Exercise	0.00	23,900	0	117,684	Jun 30 04:07 PM
Burns James William	Chief Legal Officer	Jun 28	Option Exercise	0.00	5,750	0	31,992	Jun 30 04:09 PM
Goff Brian	Chief Executive Officer	Jun 28	Option Exercise	0.00	25,528	0	25,528	Jun 30 04:05 PM
Gheuens Sarah	Chief Medical Officer	Jun 28	Option Exercise	0.00	5,750	0	25,866	Jun 30 04:06 PM
Jones Cecilia	Chief Financial Officer	Jun 28	Option Exercise	0.00	5,380	0	5,380	Jun 30 04:03 PM
Milanova Tsveta	Chief Commercial Officer	Jun 28	Option Exercise	0.00	5,449	0	5,449	Jun 30 04:02 PM
Foster-Cheek Kaye I	Director	Jun 21	Option Exercise	0.00	4,975	0	11,524	Jun 23 04:38 PM
Ho Maykin	Director	Jun 21	Option Exercise	0.00	4,975	0	11,524	Jun 23 04:37 PM
Scadden David	Director	Jun 21	Option Exercise	0.00	4,975	0	12,095	Jun 23 04:36 PM
Schenkein David P	Director	Jun 21	Option Exercise	0.00	4,975	0	122,854	Jun 23 04:34 PM
FOUSE JACQUALYN A	Director	Apr 08	Option Exercise	0.00	15,933	0	98,515	Apr 12 04:17 PM
Schenkein David P	Director	Apr 03	Option Exercise	9.05	16,363	148,085	134,242	Apr 05 04:03 PM
Schenkein David P	Director	Apr 03	Sale	22.85	16,363	373,895	117,879	Apr 05 04:03 PM
Schenkein David P	Director	Mar 27	Option Exercise	9.05	20,000	181,000	137,879	Mar 29 09:30 PM
Schenkein David P	Director	Mar 27	Sale	22.15	20,000	443,000	117,879	Mar 29 09:30 PM
Schenkein David P	Director	Mar 13	Option Exercise	9.05	20,000	181,000	137,879	Mar 15 05:11 PM
Schenkein David P	Director	Mar 13	Sale	22.49	20,000	449,817	117,879	Mar 15 05:11 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03	Sale	24.29	504	12,242	2,741	Mar 07 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01	Option Exercise	0.00	777	0	3,518	Mar 03 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 01	Option Exercise	0.00	3,833	0	21,250	Mar 03 04:05 PM
Schenkein David P	Director	Feb 27	Option Exercise	9.05	20,000	181,000	137,879	Mar 01 04:06 PM
Schenkein David P	Director	Feb 27	Sale	25.37	20,000	507,400	117,879	Mar 01 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 16	Sale	27.21	233	6,340	2,668	Feb 21 04:05 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Option Exercise	0.00	360	0	3,532	Feb 16 04:04 PM
FOUSE JACQUALYN A	Director	Feb 14	Option Exercise	0.00	11,333	0	86,230	Feb 16 04:03 PM
Burns James William	Chief Legal Officer	Feb 14	Option Exercise	0.00	1,738	0	24,147	Feb 16 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Sale	28.59	504	14,409	2,901	Feb 16 04:04 PM
Schenkein David P	Director	Feb 13	Option Exercise	9.05	20,000	181,000	137,879	Feb 15 04:03 PM
Schenkein David P	Director	Feb 13	Sale	28.62	20,000	572,400	117,879	Feb 15 04:03 PM
Burns James William	Chief Legal Officer	Feb 10	Option Exercise	0.00	1,834	0	23,052	Feb 14 04:07 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 10	Option Exercise	0.00	777	0	3,445	Feb 14 04:06 PM
Schenkein David P	Director	Jan 30	Option Exercise	9.05	20,000	181,000	137,879	Feb 01 04:04 PM
Schenkein David P	Director	Jan 30	Sale	29.33	20,000	586,578	117,879	Feb 01 04:04 PM
Schenkein David P	Director	Jan 17	Option Exercise	9.05	20,000	181,000	137,879	Jan 19 04:03 PM
Schenkein David P	Director	Jan 17	Sale	28.85	20,000	577,093	117,879	Jan 19 04:03 PM
Burns James William	Chief Legal Officer	Dec 23	Option Exercise	0.00	8,750	0	23,815	Dec 28 04:05 PM
Gheuens Sarah	Chief Medical Officer	Dec 23	Option Exercise	0.00	9,375	0	18,388	Dec 28 04:05 PM
Gheuens Sarah	Chief Medical Officer	Dec 02	Option Exercise	0.00	833	0	9,261	Dec 06 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGIO

Agios Pharmaceuticals Inc

Upgrade your FINVIZ experience